Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hansoh Pharmaceutical has announced that its fifth New Drug Application for Ameile, a third-generation EGFR-TKI drug, has been accepted by China’s National Medical Products Administration. This innovative treatment is aimed at adult patients with specific types of non-small cell lung cancer. Ameile represents a significant development in the pharmaceutical market, boosting Hansoh’s profile in cancer treatment innovations.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.